Literature DB >> 12776783

Newborn screening: an overview.

Eileen Carreiro-Lewandowski1.   

Abstract

The ethical considerations and the criteria for inclusion of a test to a newborn screening program have remained constant since testing began in the 1960s. Does the test identify a treatable disorder with significant incidence to pose a public health risk and warrant testing all babies in that state or territory? Technological advances in testing, particularly with the improvement of tandem mass spectrometry techniques and the advent of DNA testing for the specific gene mutations, have expanded our understanding of many inherited metabolic diseases. These mostly autosomal recessive disorders went under-diagnosed by the medical community for many years. This was partly due to the notion that the incidence of inherited metabolic diseases was quite rare and that many so-called birth defects, or unexplained infant deaths, were not associated with any known metabolic disorders. Public health departments, as part of their newborn health programs, offer some newborn screening to all infants born within their jurisdiction. Two tests, those for phenylketonuria (PKU) and congenital hypothyroidism are universally mandated (51/51 juristictions). The next highest frequency tests are for galactosemia and sickle cell disease (50/51), with up to thirty tests available in some states. However, the authority as to which tests are included resides with the local state government, either as a matter of law or as a matter for the public health department. As these matters become more complex, many public health officials and pediatric healthcare practitioners urge the Federal government to become involved and develop national guidelines in an effort to streamline the process and decrease the existing inconsistencies between states. For many laboratorians, the collection of newborn screening blood spot samples is the extent of their involvement in newborn screening programs. The many facets of these programs, the status of newborn screening in the United States, and the incidence and description of selected inherited disorders are explored.

Entities:  

Mesh:

Year:  2002        PMID: 12776783

Source DB:  PubMed          Journal:  Clin Lab Sci        ISSN: 0894-959X


  5 in total

1.  Genetic testing and counseling for hereditary neurological diseases in Mali.

Authors:  Katherine Gloria Meilleur; Souleymane Coulibaly; Moussa Traoré; Guida Landouré; Alison La Pean; Modibo Sangaré; Fanny Mochel; Siona Traoré; Kenneth H Fischbeck; Hae-Ra Han
Journal:  J Community Genet       Date:  2011-02-22

2.  Comparison of measurements of autoantibodies to glutamic acid decarboxylase and islet antigen-2 in whole blood eluates from dried blood spots using the RSR-enzyme linked immunosorbent assay kits and in-house radioimmunoassays.

Authors:  Anders Persson; Charlotte Becker; Ida Hansson; Anita Nilsson; Carina Törn
Journal:  Exp Diabetes Res       Date:  2010-06-03

Review 3.  The use of dried blood spots for characterizing children's exposure to organic environmental chemicals.

Authors:  Dana Boyd Barr; Kurunthachalam Kannan; Yuxia Cui; Lori Merrill; Lauren M Petrick; John D Meeker; Timothy R Fennell; Elaine M Faustman
Journal:  Environ Res       Date:  2021-01-25       Impact factor: 6.498

4.  Has the Human Genome Project Delivered for Healthcare?

Authors:  Vanessa Sivam
Journal:  Ann Med Surg (Lond)       Date:  2012-10-24

5.  Combining newborn metabolic and DNA analysis for second-tier testing of methylmalonic acidemia.

Authors:  Gang Peng; Peidong Shen; Neeru Gandotra; Anthony Le; Eula Fung; Laura Jelliffe-Pawlowski; Ronald W Davis; Gregory M Enns; Hongyu Zhao; Tina M Cowan; Curt Scharfe
Journal:  Genet Med       Date:  2018-09-13       Impact factor: 8.822

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.